Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir
- PMID: 11897580
- PMCID: PMC127114
- DOI: 10.1128/AAC.46.4.991-995.2002
Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir
Abstract
The nucleotide phosphonates cidofovir (CDV) and cyclic cidofovir (cCDV) are potent antiviral compounds when administered parenterally but are not well absorbed orally. These compounds have been reported to have activity against orthopoxvirus replication in vitro and in animal models when administered parenterally or by aerosol. To obtain better oral activity, we synthesized a novel series of analogs of CDV and cCDV by esterification with two long-chain alkoxyalkanols, 3-hexadecyloxy-1-propanol (HDP-CDV; HDP-cCDV) or 3-octadecyloxy-1-ethanol (ODE-CDV; ODE-cCDV). Their activities were evaluated and compared with those of CDV and cCDV in human foreskin fibroblast (HFF) cells infected with vaccinia virus (VV) or cowpox virus (CV) using a plaque reduction assay. The 50% effective concentrations (EC(50)s) against VV in HFF cells for CDV and cCDV were 46.2 and 50.6 microM compared with 0.84 and 3.8 microM for HDP-CDV and HDP-cCDV, respectively. The EC(50)s for ODE-CDV and ODE-cCDV were 0.20 and 1.1 microM, respectively. The HDP analogs were 57- and 13-fold more active than the parent nucleotides, whereas the ODE analogs were 231- and 46-fold more active than the unmodified CDV and cCDV. Similar results were obtained using CV. Cytotoxicity studies indicated that although the analogs were more toxic than the parent nucleotides, the selective index was increased by 4- to 13-fold. These results indicate that the alkoxyalkyl esters of CDV and cCDV have enhanced activity in vitro and need to be evaluated for their oral absorption and efficacy in animal models.
Figures

Similar articles
-
Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro.Antimicrob Agents Chemother. 2004 May;48(5):1869-71. doi: 10.1128/AAC.48.5.1869-1871.2004. Antimicrob Agents Chemother. 2004. PMID: 15105146 Free PMC article.
-
Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro.Antimicrob Agents Chemother. 2005 Sep;49(9):3724-33. doi: 10.1128/AAC.49.9.3724-3733.2005. Antimicrob Agents Chemother. 2005. PMID: 16127046 Free PMC article.
-
Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir.Antimicrob Agents Chemother. 2004 Feb;48(2):404-12. doi: 10.1128/AAC.48.2.404-412.2004. Antimicrob Agents Chemother. 2004. PMID: 14742188 Free PMC article.
-
In vitro activity of potential anti-poxvirus agents.Antiviral Res. 2003 Jan;57(1-2):35-40. doi: 10.1016/s0166-3542(02)00198-5. Antiviral Res. 2003. PMID: 12615301 Free PMC article. Review.
-
A review of compounds exhibiting anti-orthopoxvirus activity in animal models.Antiviral Res. 2003 Jan;57(1-2):41-52. doi: 10.1016/s0166-3542(02)00199-7. Antiviral Res. 2003. PMID: 12615302 Free PMC article. Review.
Cited by
-
Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures.Antimicrob Agents Chemother. 2006 Jul;50(7):2525-9. doi: 10.1128/AAC.01489-05. Antimicrob Agents Chemother. 2006. PMID: 16801436 Free PMC article.
-
Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovir.Antiviral Res. 2007 Jul;75(1):87-90. doi: 10.1016/j.antiviral.2006.09.005. Epub 2006 Oct 10. Antiviral Res. 2007. PMID: 17367874 Free PMC article.
-
Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro.Antimicrob Agents Chemother. 2004 May;48(5):1869-71. doi: 10.1128/AAC.48.5.1869-1871.2004. Antimicrob Agents Chemother. 2004. PMID: 15105146 Free PMC article.
-
Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.Clin Microbiol Rev. 2003 Oct;16(4):569-96. doi: 10.1128/CMR.16.4.569-596.2003. Clin Microbiol Rev. 2003. PMID: 14557287 Free PMC article. Review.
-
Camelpox, an emerging orthopox viral disease.Indian J Virol. 2013 Dec;24(3):295-305. doi: 10.1007/s13337-013-0145-0. Epub 2013 Jul 16. Indian J Virol. 2013. PMID: 24426291 Free PMC article.
References
-
- Bischofberger, N., M. J. M. Hitchcock, M. S. Chen, D. B. Barkhimer, K. C. Cundy, K. M. Kent, S. A. Lacy, W. A. Lee, Z.-H. Li, D. B. Mendel, D. F. Smee, and J. L. Smith. 1994. 1-[((s)-2-Hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, with improved therapeutic index in vivo. Antimicrob. Agents Chemother. 38:2387-2391. - PMC - PubMed
-
- Bray, M., M. Martinez, D. F. Smee, D. Kefauver, E. Thompson, and J. W. Huggins. 2000. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenges. J. Infect. Dis. 181:10-19. - PubMed
-
- Breman, J. G., and D. A. Henderson. 1998. Poxvirus dilemmas--monkeypox, smallpox, and biological terrorism. N. Engl. J. Med. 339:556-559. - PubMed
-
- Cundy, K. C., A. M. Bidgood, G. Lynch, J.-P. Shaw, L. Griffin, and W. A. Lee. 1996. Pharmacokinetics, bioavailability, metabolism and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab. Disp. 24:745-752. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources